Health Canada - Federal department responsible for drug approvals and health regulation in Canada
显示 2024 年的审批记录
仅限当前页。暂不支持搜索完整审批数据集。
药物名称 | 公司 | 适应症 | 日期 | 类型 |
|---|---|---|---|---|
| APO-LEVOTHYROXINE | Apotex Inc | Marketed | Mar 7, 2025 | Marketed |
| M-TRANYLCYPROMINE | mantra pharma inc | Marketed | Mar 7, 2025 | Marketed |
| MINT-VENLAFAXINE XR | mint pharmaceuticals inc | Marketed | Mar 6, 2025 | Marketed |
| MINT-VENLAFAXINE XR | mint pharmaceuticals inc | Marketed | Mar 6, 2025 | Marketed |
| MINT-VENLAFAXINE XR | mint pharmaceuticals inc | Marketed | Mar 6, 2025 | Marketed |
| PMS-LEVODOPA-CARBIDOPA | Pharmascience Inc | Marketed | Mar 5, 2025 | Marketed |
| PMS-LEVODOPA-CARBIDOPA | Pharmascience Inc | Marketed | Mar 5, 2025 | Marketed |
| PMS-LEVODOPA-CARBIDOPA | Pharmascience Inc | Marketed | Mar 5, 2025 | Marketed |
| XOFLUZA | Hoffmann-La Roche Limited | Marketed | Mar 5, 2025 | Marketed |
| WOMEN'S HAIR REGROWTH TREATMENT | Taro Pharmaceuticals Inc | Marketed | Mar 4, 2025 | Marketed |
| MEN'S MINOXIDIL FOAM | Taro Pharmaceuticals Inc | Marketed | Mar 4, 2025 | Marketed |
| CLOROTEKAL | B. Braun Melsungen AG | Marketed | Mar 4, 2025 | Marketed |
| OMLYCLO | Celltrion Inc | Marketed | Mar 4, 2025 | Marketed |
| TALVEY | Janssen Inc | Marketed | Mar 4, 2025 | Marketed |
| TALVEY | Janssen Inc | Marketed | Mar 4, 2025 | Marketed |
| OMLYCLO | Celltrion Inc | Marketed | Mar 4, 2025 | Marketed |
| TARO-DEFERIPRONE | Taro Pharmaceuticals Inc | Marketed | Mar 3, 2025 | Marketed |
| TARO-TOFACITINIB XR | Taro Pharmaceuticals Inc | Marketed | Mar 3, 2025 | Marketed |
| LAIT VISAGE & CORPS | pierre fabre dermo-cosmetique canada inc | Marketed | Mar 3, 2025 | Marketed |
| LAIT FAMILLE - VISAGE & CORPS | pierre fabre dermo-cosmetique canada inc | Marketed | Mar 3, 2025 | Marketed |
